[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ocular-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ocular-diseases":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,73,93,112,140,169],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100594843","4d-duke-microscope-integrated-optical-coherence-tomography-in-a-zeiss-artevo-800-100594843",false,"NCT07024719","4D Duke Microscope Integrated Optical Coherence Tomography in a Zeiss Artevo 800","First Use of Duke 4D Microscope Integrated OCT (MIOCT) Integrated Into Zeiss Artevo 800 Ophthalmic Surgical Microscope in the Operating Room","4D MIOCT","Inclusion Criteria:\n\n* Adult participants 18 years of age and older\n* Patients undergoing surgery for ocular disease\n* Adults able and willing to give informed consent to participate in the study\n\nExclusion Criteria:\n\n* Patients with any ocular disease that restricts the ability to perform OCT scanning","ALL","18 Years",{"count":20,"type":21},5,"ESTIMATED","INTERVENTIONAL",[24],"NA","The study team will conduct the first in-human pilot studies using 4D MIOCT for imaging in the operating room. Building on the earlier integration and wet-lab validations, the researchers will assess the system's ease of use, safety, and visualization of intended structures during various anterior and posterior segment ophthalmic procedures.",[27,28,29],"Corneal Diseases","Retinal Diseases","Ocular Diseases",[31,32,33],"Microscope integrated OCT","intraoperative OCT","optical coherence tomography (OCT)","RECRUITING","2026-01-14",{"date":37,"type":38},"2026-01-16","ACTUAL",{"date":40,"type":38},"2025-07-24",{"date":42,"type":21},"2026-10",{"name":44,"class":45},"Duke University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":20},"100574113","ophthalmic-ai-assisted-medical-decision-making-100574113","NCT06755060","Ophthalmic AI-Assisted Medical Decision-Making","A Study on Ophthalmic Multimodal AI-Assisted Medical Decision-Making Based on Imaging and Electronic Medical Record Data","Inclusion Criteria:\n\n1. Age Criteria: No age restrictions apply for inclusion in the study.\n2. Ophthalmic Disease Diagnosis: Eligible patients must have a diagnosis of one or more ophthalmic conditions, with the diagnosis confirmed by a qualified ophthalmologist.\n3. Imaging and Clinical Data Requirements: Patients must be able to provide complete ophthalmic imaging data and electronic medical records (EMR) that are comprehensive and accessible for the purposes of the study.\n4. Informed Consent: All patients, or their legal representatives in the case of minors or individuals unable to provide informed consent, must sign a consent form that clearly outlines the study's objectives, procedures, potential risks and discomforts, data usage, and the rights and responsibilities of participants. In the case of minors or those unable to consent, informed consent must be obtained from the patient's legal guardian.\n5. Treatment Adherence: Participants must demonstrate the ability to understand and adhere to the study's requirements, including compliance with follow-up visits, examination schedules, and treatment recommendations. Patients must agree to participate in regular assessments and data collection, including imaging exams, laboratory tests, and follow-up evaluations as required by the study protocol.\n6. Clinical Physician Assessment: The attending physician must determine that the patient meets all inclusion criteria and has the capacity to comply with the necessary treatment, diagnostic tests, and follow-up protocols throughout the study duration.\n\nExclusion Criteria:\n\n1. Acute or Severe Ocular Diseases: Patients with acute ocular conditions requiring immediate medical intervention, which necessitate exclusion from interventional studies due to the urgency of their treatment.\n2. Serious Systemic Diseases: Patients with serious systemic illnesses that may interfere with the treatment of ocular diseases, impact the effectiveness of the intervention, or complicate the interpretation of study outcomes.\n3. Prior Exposure to Study Interventions: Patients who have previously undergone the intervention being studied or participated in other experimental treatments within ongoing clinical trials, as this may introduce bias or confound the study results.\n4. Incomplete Imaging or Clinical Data: Patients who are unable to provide complete or adequate ophthalmic imaging data or lack a comprehensive electronic medical record (EMR), which are essential for the integrity of the study data.\n5. Pregnancy or Lactation: Pregnant or breastfeeding women, for whom there may be potential risks associated with ocular treatment or imaging procedures. Such cases will be evaluated on an individual basis to ensure patient safety.\n6. Mental Health or Cognitive Impairment: Patients diagnosed with significant mental health disorders or cognitive impairments that prevent them from fully understanding the nature and risks of the study, or from complying with the treatment regimen and follow-up procedures.\n7. Drug Allergies or Severe Reactions: Patients with known allergies or severe adverse reactions to any medications or ophthalmic treatments likely to be used during the study, which could pose a health risk to the patient.\n8. Current Participation in Other Clinical Trials: Patients who are concurrently involved in other interventional clinical trials (especially those related to ophthalmology), as this may lead to conflicting treatments or interfere with the assessment of the study's outcomes.\n9. Inability to Comply with Follow-up Requirements: Patients who, due to logistical, health-related, or personal factors, are unable to comply with the required follow-up visits, treatment regimens, or data collection, which are essential for the study's longitudinal analysis.\n10. Other Clinical Exclusions: Patients whose participation, based on the clinical judgment of the treating physician, may not be in their best interest due to their health condition or other factors, or who may experience adverse outcomes from participating in the study.",true,{"count":56,"type":21},100000,[24],"This is a multi-center, prospective clinical study designed to evaluate the application and effectiveness of an AI-assisted medical decision support system, leveraging multimodal data fusion, in ophthalmic clinical practice.",[29],[61,62,63],"ocular diseases","Ophthalmic Multimodal AI-Assisted Medical Decision-Making","Artificial Intelligence","2025-08-15",{"date":66,"type":38},"2025-08-20",{"date":68,"type":38},"2024-12-01",{"date":70,"type":21},"2026-12-30",{"name":72,"class":45},"The Eye Hospital of Wenzhou Medical University",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":46},"100580254","usability-user-testing-of-the-easy-eyefm-ai-platform-100580254","NCT06834906","Usability User Testing of the Easy-EyeFM AI Platform","Inclusion Criteria:\n\n* Medical students or doctors\n* Have enough time to participate in this program, about 1 hour continuous assessment\n* Agree to sign the informed consent form\n\nExclusion Criteria:\n\n* Poor computer and mobile phone use and reading ability\n* Poor language expression or dialect category is not included in the speech recognition function of the platform","80 Years",{"count":81,"type":21},84,[24],"Easy-EyeFM is a code-free artificial intelligence platform designed for ophthalmologists to provide diagnostic and treatment recommendations and help doctors develop customized diagnostic models.\n\nThis project aims to evaluate the usability and user-friendliness of the Easy-EyeFM platform for physicians. The study will gather feedback from medical professionals to evaluate the intuitiveness and effectiveness of the platform in supporting model customization and medical image analysis tasks.\n\nSubjects will participate in the trial of the Easy-EyeFM platform and the comparison with the existing commercial platform (AutoML) at the appointed time. The researchers will inform subjects of relevant precautions and assist them to read the user manual before the test. Subjects will complete model customization and picture diagnosis within the prescribed test time, and according to the test results, Score the human-computer interaction experience of the AI platform, fill in the questionnaire, and finally complete the evaluation content.",[29],"2025-08-14",{"date":64,"type":38},{"date":88,"type":38},"2025-01-26",{"date":90,"type":21},"2025-09",{"name":92,"class":45},"Tsinghua University",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":62,"officialTitle":52,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":20},"100574123","ophthalmic-multimodal-ai-assisted-medical-decision-making-100574123","NCT06755190","Inclusion Criteria:\n\n1.All patients who have received treatment at multiple centers, including The Eye Hospital of Wenzhou Medical University, First Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, ZhuHai Hospital, and Macau University of Science and Technology Hospital.\n\n2.Availability of comprehensive electronic health records (EHR), including: Ophthalmic images (e.g., fundus photography, OCT, or slit-lamp images). Electronic medical records (e.g., diagnosis, treatment, and follow-up notes). Examination results (e.g., visual acuity, intraocular pressure, or laboratory tests). 3.Patients with a clear and confirmed diagnosis of one or more ocular diseases. 4.Patients with sufficient follow-up records to allow assessment of disease progression or prognosis, if applicable.\n\n1. All ophthalmology patients who have previously received treatment at the Department of Ophthalmology, the Eye Hospital of Wenzhou Medical University, First Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, Zhuhai People's Hospital, and the University Hospital.\n2. Availability of comprehensive electronic health records (EHR), including: Ophthalmic images (e.g., fundus photography, OCT, or slit-lamp images). Electronic medical records (e.g., diagnosis, treatment, and follow-up notes). Examination results (e.g., visual acuity, intraocular pressure, or laboratory tests).\n3. Patients with a clear and confirmed diagnosis of one or more ocular diseases.\n4. Patients with sufficient follow-up records to allow assessment of disease progression or prognosis, if applicable.\n\nExclusion Criteria:\n\n1. Incomplete or missing critical EHR components.\n2. Cases with ambiguous or unverified diagnoses that cannot be clearly categorized.\n3. Duplicated or redundant data from the same patient.",{"count":99,"type":21},5000000,"OBSERVATIONAL","This is a multi-center, retrospective clinical study designed to evaluate the application and effectiveness of an AI-assisted medical decision support system, leveraging multimodal data fusion, in ophthalmic clinical practice.",[29],[61,62,63],"2025-04-16",{"date":106,"type":38},"2025-04-17",{"date":108,"type":38},"2024-12-20",{"date":110,"type":21},"2025-05",{"name":72,"class":45},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100578319","phase-2-evaluating-efficacy-and-safety-of-oral-melatonin-in-acute-central-serous-chorioretinopathy-100578319","NCT06809751","Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy","Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy (CSCR): a Double-blind Randomized Clinical Trial","Inclusion Criteria:\n\n1. Patients whose diagnosis of central serous chorioretinopathy is confirmed based on clinical and imaging criteria within the past 6 weeks\n2. Patients with minimum age of 18 years old\n3. Consent to participate in the study\n\nExclusion Criteria:\n\n1. A history of vitrectomy\n2. A history of laser surgery in the eye being studied in the past 3 months\n3. A history of anti-VEGF injection in the eye being studied in the past 3 months\n4. History of patient suspicious for choroidal neovascularization (CNV)\n5. Pregnant or nursing patients\n6. Patients with significantly compromised visual acuity in the eye being studied due to concomitant ocular condition\n7. Patients participating in any other investigational drug study\n8. Inability to obtain OCT photographs",{"count":120,"type":21},48,[122,123],"PHASE2","PHASE3","The goal of this clinical trial is to learn if oral melatonin can enhance visual acuity and central macular thickness in central serous chorioretinopathy (CSCR) in adults. The main questions it aims to answer are:\n\n1. How does melatonin affect central macula thickness in CSCR?\n2. How does melatonin affect visual acuity in CSCR? Researchers will compare placebo (a look-like substance that contains no drug) to see if melatonin works to treat CSCR.\n\nParticipants will:\n\n1. Take melatonin or placebo twice a day for one month\n2. Visit the clinic after finishing a course of treatment, and 1 and 3 months after that for visual acuity assessment and tests\n3. Keep a diary of their symptoms",[126,127,29,128,129],"Central Serous Chorioretinopathy","Melatonin","Visual Acuity","Macula Abnormality","NOT_YET_RECRUITING","2025-01-30",{"date":133,"type":38},"2025-02-05",{"date":135,"type":21},"2025-02-01",{"date":137,"type":21},"2025-06-01",{"name":139,"class":45},"Mohsen Pourazizi",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":147,"maxAge":18,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":152,"conditions":153,"keywords":159,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":167,"leadSponsor":168,"locationsCount":4},"100577070","phase-1-efficacy-and-safety-of-oral-probiotics-on-ocular-symptoms-and-gut-microbiome-of-children-with-vernal-keratoconjunctivitis-100577070","NCT06793514","Efficacy and Safety of Oral Probiotics on Ocular Symptoms and Gut Microbiome of Children with Vernal Keratoconjunctivitis","Efficacy and Safety of Oral Probiotics on Ocular Symptoms and Gut Microbiome of Children with Vernal Keratoconjunctivitis: a Double-blind Clinical Trial Study","Inclusion Criteria:1- Patients whose diagnosis of vernal keratoconjunctivitis is confirmed based on clinical criteria. 2-Patients with an age range of 4 to 18 years. 3-Patients who have not received drug treatment for vernal keratoconjunctivitis disease recently.\n\n\\-\n\nExclusion Criteria:1-Having other eye diseases (except refractive error) 2-Change in the diagnosis of the disease during the study 3-Antibiotics, anti-inflammatory drugs, immunosuppressive drugs 4-History of known gastrointestinal diseases (such as IBD, Celiac,...) 5- History of digestive problems in the last two weeks 6- Lack of consent to participate in the study 7- Having an eye infection in the last one month 8- People who were athletes or involved in intense physical activity 9- Smoking, alcohol and drugs. 10- Using drugs that affect appetite, bowel movements, and nutrient absorption 11- Using prebiotics, probiotics or synbiotics in the last 3 months 12- People who have been on a diet to lose or gain weight in the last 3 months 13- People who have undergone gastrointestinal surgery. 14- Changing the patient's diagnosis in the course of treatment 15- Failure to follow up the patient at the specified times for the visit and assessment of the patient's bed 16- Taking fat-reducing drugs 17-Oral hypoglycemic drugs, insulin, antihypertensive drugs-18- Diuretics, laxatives, antacids 19-Food supplements in the last 3 months.\n\n\\-","4 Years",{"count":149,"type":21},32,[151],"PHASE1","The primary goal of this study is to determine the effects of oral probiotics on the severity of ocular symptoms and the alterations of the gut microbiome of children (4-18 years old) with vernal keratoconjunctivitis. The current study will also assess the safety of oral probiotics among children with vernal keratoconjunctivitis. The main questions it aims to answer: 1- Does treatment with oral probiotics improve the severity of ocular symptoms in children with vernal keratoconjunctivitis? 2- Does treatment with oral probiotics alter the gut microbiome of children with vernal keratoconjunctivitis? Researchers will compare the ocular symptoms and gut microbiome between two groups receiving oral probiotics and placebo among children with vernal keratoconjunctivitis.\n\nParticipants The participants will receive the oral probiotics and placebo ever day for one month.\n\nRecord their regimen and keep a diary of their symptoms.",[154,155,29,156,157,158],"Probiotic","Ocular Surface Disease","Ocular Dryness","Gut Microbiome Dysbiosis","Gut -microbiota",[154,160,161,162],"Vernal keratoconjunctivitis","Clinical trial","gut microbiome","2025-01-21",{"date":165,"type":38},"2025-01-27",{"date":135,"type":21},{"date":137,"type":21},{"name":139,"class":45},{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":54,"sex":17,"minAge":177,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":181,"conditions":182,"keywords":192,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":46},"100357508","hamburg-city-health-study---a-german-cohort-study-100357508","NCT03934957","Hamburg City Health Study - a German Cohort Study","A Single Center, Prospective, Epidemiologic Cohort Study With Emphasis on Imaging to Improve the Identification of Individuals at Risk for Major Chronic Diseases and to Improve Early Diagnosis and Survival","HCHS","Inclusion Criteria:\n\n* Inhabitant of the city of Hamburg at the time of inclusion into the study (Inclusion is time of written consent)\n* Age 45 to 74 years\n* Personally signed informed consent\n\nExclusion Criteria:\n\n* Insufficient knowledge of the German language, in order to understand study documents and computer assisted interview without translation\n* Physical or psychological incapability to travel to the study center and to cooperate in the investigations","45 Years","74 Years",{"count":180,"type":21},45000,"The Hamburg City Health Study (HCHS) is a large, prospective, long-term, population-based cohort study and a unique research platform and network to obtain substantial knowledge about several risk and prognostic factors in major chronic diseases.",[183,184,185,186,187,188,189,29,190,191],"Coronary Heart Disease","Stroke","Dementia","Cancer","Health Care","Vascular Diseases","Periodontal Diseases","Respiratory Disease","Obesity",[193,194,195,196,197],"Epidemiology","prospective cohort study","Nutrition","prevention","psychiatric and psychosomatic disorders","2019-04-28",{"date":200,"type":38},"2019-05-02",{"date":202,"type":38},"2016-02-08",{"date":204,"type":21},"2028-12-31",{"name":206,"class":45},"Universitätsklinikum Hamburg-Eppendorf"]